Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma

Clinical Infectious Diseases

Volumn 37, Issue 6, 2003, Pages 820-827

  Simonelli, Cecilia ^a   Zanussi, Stefania ^a   Cinelli, Roberta ^a   Dal Maso, Luigino ^a   Di Gennaro, Giampiero ^a   D'Andrea, Monica ^a   Nasti, Guglielmo ^a   Spina, Michele ^a   Vaccher, Emanuela ^a   De Paoli, Paolo ^a   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DIDANOSINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PREDNISONE; PROTEINASE INHIBITOR; RITONAVIR; RITUXIMAB; SAQUINAVIR; STAVUDINE; VINCRISTINE; ZIDOVUDINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; EVALUATION; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIREMIA; VIROLOGY; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; VINCRISTINE; VIRAL LOAD; VIREMIA;

EID: 0141453197     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/377204     Document Type: Article

References (24)

1. Thiessard F, Morlat P, Marimoutou C, et al. Prognostic factors after non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Cancer 2000; 88:1696-702.
2. Conti S, Masocco M, Pezzotti P, et al. Differential impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-defining illnesses. J Acquir Immune Defic Syndr 2000; 25:451-8.
3. Navarro T, Ribera JM, Oriol A, et al. Favorable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphoma. Leuk Lymphoma 2002; 43:1837-42.
4. Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. The EuroSIDA Study Group. Blood 2001; 98:3406-12.
5. Gates AE, Kaplan LD. AIDS malignancies in the era of highly active an tiretroviral therapy. Oncology (Huntingt) 2002; 16:441-51, 456, 459.
6. Levine AM. Acquired immunodeficiency syndrome-related lymphoma: clinical aspects. Semin Oncol 2000; 27:442-53.
7. Tam HK, Zhang ZF, Jacobson LP, et al. Effect of highly active anti-retroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer 2002; 98:916-22.
8. Gerard L, Galicier L, Maillard A, et al. Systemic non-Hodgkin's lymphoma in HIV-infected patients with effective suppression of HIV-replication: persistent occurrence but improved survival. J Acquit Immune Defic Syndr 2002; 30:478-84.
9. Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98:2339-44.
10. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1002-6.
11. Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19:2171-8.
12. Mackall C, Fleisher T, Brown M, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994; 84:2221-8.
13. + suppressor-inducer T-cells. Cancer Res 1988; 48:1671-5.
14. Zanussi S, Simonelli C, D'Andrea M, et al. The effects of antineoplastic chemotherapy on HIV disease. AIDS Res Hum Retroviruses 1996; 12:1703-7.
15. Powles T, Imami N, Nelson M, Gazzard BG, Bower M. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS 2002; 16:531-6.
16. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001; 91:155-63.
17. Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001; 15:1483-91.
18. Cunningham S, Ank B, Lewis D, et al. Performance of the applied biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples. J Clin Microbiol 2001; 39:1254-7.
19. Shafer RW, Jung DR, Betts BJ. Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries. Nat Med 2000; 6:1290-2.
20. D'Aquila RT, Schapiro JM, Brun-Vézinet F, et al. Drug resistance mutations in HIV-1. Top HIV Med 2002; 10:21-5.
21. Little RF, Pittalunga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101:4653-9.
22. Grabar S, Pradier C, Le Corfec E, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 2000; 14:141-9.
23. Mocroft A, Devereux H, Kinloch-de-Loes S, et al. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. AIDS 2000; 14:1545-52.
24. Moore AL, Youle M, Lipman M, et al. Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure? AIDS 2002; 16:615-8.